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AbstrAct
background Bisphosphonate-related osteonecrosis of 
the jaw (BRONJ) is a rare, yet signiicant, adverse effect 
of bisphosphonate therapy. A multidisciplinary approach 
to the prevention of BRONJ is recommended due to the 
signiicant morbidity and dificulty treating the condition. 
Current evidence suggests that both general practitioners 
(GPs) and community pharmacists have limited knowledge 
relating to BRONJ and that preventative strategies are 
rarely implemented.
Objective To explore the attitudes and perceptions of GPs 
and community pharmacists on the risks and preventative 
strategies for the development of BRONJ.
Design Interpretivist methodological approach using 
qualitative semistructured interviews.
Participants 9 community pharmacists and 8 GPs.
setting Primary Care in North East England and Cumbria, 
UK.
Methods Using a Grounded Theory methodology 
and integrating a process of constant comparison in 
the iterative enrichment of data sets, semistructured 
interviews were undertaken, transcribed and analysed 
using framework analysis. Salient themes were identiied 
and related back to extant literature in the ield.
results Four salient and inter-related themes emerged: 
(1) uncertain knowledge, indicating limited exposure 
of respondents to BRONJ, and limited awareness 
of the implications of its diagnosis, risk factors and 
preventative strategies; (2) patient speciic, referring to the 
complexity of patients, patient education and prioritising 
aspects of care; (3) wider context, indicating a lack of 
interdisciplinary communication and referral processes 
between professions, workload pressures, access and 
patient receptivity to dental services; and (4) professional, 
relecting professional roles and responsibilities, authority 
and educational initiatives
conclusions Effective communication or collaborative 
care between GPs and community pharmacists for the 
prevention of BRONJ is not apparent. Interventions to 
mitigate against the risk of developing BRONJ and clarity 
of GP and community pharmacy roles are required.
IntrODuctIOn
Bisphosphonates are a class of drugs used in 
a variety of therapeutic indications, such as 
osteoporosis, Paget’s disease, hypercalcaemia 
of malignancy, osteolytic bone metastases and 
osteolytic lesions of multiple myeloma.1 In 
practice, they are most commonly prescribed 
in the management of osteoporosis.
The prescribing of bisphosphonates has 
increased considerably over recent years. 
Statistical evaluation of prescribing in England 
reveals a rise of 122.6% in the number of indi-
vidual prescription items dispensed between 
2004 and 2014.2 Alendronic acid is the most 
commonly prescribed bisphosphonate, with 
7 391 000 individual dispensations in 2014.2 
This rise may be attributable to increases 
in the proportion of elderly people in the 
UK population, publication of guidance 
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Research
strengths and limitations of this study
 Ź Although bisphosphonate-related osteonecrosis of 
the jaw is not a common inding, affected patients 
experience signiicant morbidity, and management 
of this condition warrants further study to stimulate 
improved patient care.
 Ź A qualitative approach yielded rich data through in-
depth semistructured interviews with two groups 
of healthcare professionals (general practitioners 
and community pharmacists). Constant comparison 
with concurrent data collection and analysis allowed 
further exploration and reining of emerging themes.
 Ź A study limitation was that, although consistent 
with the methodological approach, the sample size 
was relatively small. Furthermore, the study was 
conducted in the North East of England and Cumbria, 
which may impact on transferability of the indings 
to other settings.
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recommending the prescribing of bisphosphonates and 
the availability of generic products. Risk for bisphospho-
nate-related osteonecrosis of the jaw (BRONJ) in people 
taking bisphosphonates is hypothesised to be related to 
the unique nature of the blood supply, structure and func-
tion of the jaw bones.3 Case reports of BRONJ emerged 
in the early 2000s; it is now well documented in the liter-
ature,4 and has been subject to a number of prescribing 
safety alerts in recent years.3 5
The actual incidence and prevalence rates of BRONJ 
are difficult to quantify, with varying reports in the 
literature. This is potentially attributable to a low inci-
dence of reporting, the variance in diagnostic criteria 
and a percentage of mild self-resolving cases remaining 
undiagnosed. A nationwide study in the UK of patients 
presenting to departments of oral surgery, oral medicine, 
oral and maxillofacial surgery and dental hospitals iden-
tified 369 cases of BRONJ over a specified 2-year period. 
Oral bisphosphonates had been prescribed for 56% of 
the patients. Extrapolation of these data suggests that 
the incidence of BRONJ may be 8.2–12.8 cases/million 
of the population/year, which is equivalent to 508–793 
patients/year in the UK.6
Ideally, optimal dental health should be established 
before patients commence bisphosphonate therapy.7 This 
is to prioritise care that will subsequently reduce mucosal 
trauma or act prophylactically to aid in the avoidance of 
subsequent dental extractions or conditions which may 
further predispose the patient to oral surgery or dental 
procedures that impact on the osseous structures of the 
jaw.8
Several prospective studies have identified that dental 
screening and preventative strategies reduce the risk 
of osteonecrosis of the jaw. A study by Dimopoulous9 
found a statistically significant reduction in the inci-
dence of BRONJ with the implementation of preventative 
measures and Vandone et al10 reported a 50% reduction 
in the incidence rate with screening and pretreatment 
preventative dental care.9 10 A multidisciplinary approach 
to the prevention of BRONJ is recommended in the liter-
ature for the management of patients requiring bisphos-
phonate therapy,11 12 incorporating both patient and 
health professional education of the risk of the devel-
opment of BRONJ.5 Education of dentists, pharmacists, 
general practitioners (GPs) and patients about BRONJ 
is indicated,13 with specific emphasis on the provision of 
focused preventative measures and detailed oral hygiene 
instructions.14
Available published evidence describing the attitudes 
of both GPs and pharmacists towards, and their percep-
tions of, their roles in preventive strategies for BRONJ is 
limited. A questionnaire survey of GPs (n=120) and phar-
macists (n=60) in North Wales identified that although 
both sets of healthcare professionals have regular contact 
with patients who are prescribed bisphosphonates, they 
have limited knowledge of the dental implications associ-
ated with treatment. Both groups of professionals reported 
awareness of the side effects of bisphosphonates; however, 
only 11.8% of GPs and 9.7% of pharmacists specifically 
identified osteonecrosis as a potential unwanted effect of 
therapy.15
Furthermore, even when pharmacists and GPs report 
some knowledge of BRONJ, is it not clear how this aware-
ness influences their clinical practice. The aim of this 
study was to explore the attitudes and perceptions of GPs 
and community pharmacists on the risks and preventative 
strategies for the development of BRONJ.
MethOD
Design
A Grounded Theory approach16 with constant compar-
ison was used throughout the research. Semistruc-
tured, one-to-one interviews were carried out by a single 
researcher (AS), at either the School of Pharmacy or the 
participant’s workplace, depending on participant prefer-
ence and availability. The interviews were audio-recorded 
and transcribed verbatim; field notes were not taken 
due to verbatim transcribing. Integrating a process of 
constant comparison,17 an initial topic guide (see online 
supplementary 1) was produced and refined by the 
research team; this served as a benchmark of questioning, 
which was subsequently developed iteratively as data were 
progressively enriched.
setting
Participants were recruited from a range of urban and 
rural primary care locations in the North East of England 
and Cumbria. GPs were recruited from both teaching and 
non-teaching practices and community pharmacists were 
recruited from independent (single or small-chain phar-
macies) and multiple pharmacies (companies consisting 
of numerous pharmacy stores) (table 1).
Participants
Seventeen participants, nine community pharmacists and 
eight GPs were recruited to the study. An invitation letter 
and participant information sheet (see online supple-
mentary file 2) were posted to GPs and community phar-
macists. An initial convenience sample of participants 
who responded to the invitation was implemented with 
further recruitment achieved via snowball sampling. No 
participants who responded to the invitation refused to 
participate or dropped out of the study.
Analysis
Constant comparison allowed enrichment of data and 
for new concepts to guide subsequent interviews via the 
strategic development of each subsequent topic guide. 
Adoption of Ritchie and Spencer’s framework analysis18 
allowed salient themes from the findings to be identified. 
Data were analysed by AS, using Microsoft Word 2010 
and Microsoft Excel 2010, with transcripts and emerging 
themes cross-checked for interpretation and agreed 
among the research team until saturation occurred; tran-
scripts were not returned to participants for comment 
group.bmj.com on October 12, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 3Sturrock A, et al. BMJ Open 2017;7:e016047. doi:10.1136/bmjopen-2017-016047
Open Access
Table 1 Participant characteristics—pharmacists
Participant Gender
Number of years 
since registration
Number of items 
dispensed per month
Practice 
location Independent/multiple Full/part-time
P1 Female 6–10 6000–8999 Suburban Independent Full-time
P2 Female 11–15 12 000+ Suburban Multiple Full-time
P3 Female 0–5 3000–5999 Suburban Multiple Full-time
P4 Female 21+ 3000–5999 Urban Independent Part-time
P5 Female 0–5 6000–8999 Urban Independent Full-time
P6 Female 0–5 6000–8999 Urban Independent Full-time
P7 Male 6–10 6000–8999 Urban Multiple Full-time
P8 Female 16–20 6000–8999 Rural Independent Part-time
P9 Male 11–15 6000–8999 Semirural Multiple Full-time
P, pharmacist.
Table 2 Participant characteristics—GPs
Participant Gender
Number of years 
since registration
Practice size 
(patients) Practice location
Teaching 
practice Full/part-time
GP1 Female 21+ 3000–5999 Urban Non-teaching Full-time
GP2 Male 16–20 12 000+ Urban Teaching Part-time
GP3 Male 21+ 12 000+ Suburban Teaching Part-time
GP4 Male 11–15 9000–11 999 Semirural Teaching Full-time
GP5 Female 11–15 12 000+ Suburban Teaching Part-time
GP6 Female 16–20 3000–5999 Rural Teaching Part-time
GP7 Male 21+ 9000–11 999 Semirural Teaching Full-time
GP8 Male 16–20 9000–11 999 Semirural Teaching Full-time
GP, general practitioner.
or feedback and repeat interviews were not performed. 
A sample transcript has been published alongside this 
paper (see online supplementary file 3). Framework 
analysis involved a five-stage process: (1) familiarisation 
with the data—interviews were transcribed by AS and key 
issues identified through immersion in the data; achieved 
via iterative cycles of reading and rereading of transcripts; 
(2) development of a thematic framework—the initial 
themes formed the basis of a thematic framework; (3) 
indexing data—data were indexed against the thematic 
framework; (4) charting—charts were produced of the 
data within the thematic framework; (5) mapping of the 
data—themes were reviewed until definitive concepts 
could be produced from the data.
ethics
Ethical approval was obtained from the University of 
Sunderland (Reference PHW52).
results
Seventeen healthcare professionals were included in 
this study (tables 1 and 2). Interviews were carried out 
between January and October 2016; 1 hour was desig-
nated for each interview.
Four salient inter-related themes emerged: (1) uncer-
tain knowledge—a lack of familiarity with the subject 
area, the prevalence and significance of BRONJ and 
limited exposure to the condition; (2) patient specific—
complexity of patients, clinical priorities and patient 
education; (3) wider context—access/fear of dental 
services, interprofessional communication and clinical 
workload; (4) professional—perceived responsibilities, 
authority and interprofessional education.
uncertain knowledge
All participants perceived themselves to have some degree 
of knowledge on the adverse effects that are associated 
with bisphosphonate therapy. The concept of BRONJ 
was introduced in the participant information sheet and 
opened up for discussion during the interview; partici-
pants actually had minimal knowledge on this topic but 
all were aware of the potential risk.
‘I think it was probably sitting way at the back of my 
mind…it was probably in a lecture at some point.’ 
(GP4)
Although poor dental health and the duration of 
therapy were frequently identified, all of the participants 
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had limited awareness of the risk factors for the develop-
ment of BRONJ.
‘I am not aware of any, I imagine that significant 
dental problems would be associated with it, but I am 
not actually aware of any others.’ (GP3)
Participants were uncertain on the prevalence of 
BRONJ and had limited knowledge on the significant 
morbidity associated with the condition.
‘I have never seen it, so I presume it’s not very 
common…I don’t really know how serious it is when 
it does happen.’ (P3)
One GP had first-hand experience of managing 
patients with BRONJ, and the significant morbidity that 
her patients had experienced influenced their attitude 
towards management of patients who are prescribed 
bisphosphonates. None of the other participants had 
been involved with the care of a patient with BRONJ.
‘It’s the sort of thing that once you see it, you then 
remember it. They were both very complex patients, 
but the amount of morbidity involved with the 
osteonecrosis of the jaw in both of those patients was 
considerable.’ (GP1)
Patient speciic
Patients prescribed bisphosphonates usually have a 
number of comorbidities. They are often elderly and are 
prescribed multiple medications, and their management 
can be complex. Indeed, this complexity requires that 
practitioners assign priorities in their care, relating to 
both the overall management of the patient and to more 
specific priorities related to bisphosphonates.
‘They are lower down in the pecking order of things 
that we look at when we are supervising polypharmacy, 
when we are looking at chronic disease management.’ 
(GP3)
All participants identified bisphosphonates as having 
very specific administration instructions and common 
side effects, such as gastrointestinal (GI) or oesophageal 
problems; these were the focus of consultations. However, 
participants were concerned about overloading patients 
with information and the risk of patients potentially 
refusing treatment.
‘You try not to overload them with too much 
information because you know that sometimes they 
can’t even take it on board at the best of times.’ 
(P2)
Patient education was a key issue that emerged from 
the data; participants placed importance specifically on 
the education of patients in relation to administration 
instructions and common side effects of bisphospho-
nates. This would usually take the form of a set of prede-
fined counselling points.
‘I think when you have a drug like a bisphosphonate, 
which is complex with its instruction on how to take 
it and people are tied up in that.’ (GP1)
Although some participants advised bisphosphonate 
patients to seek dental check-ups, most reported that 
many of their patients, in general, appeared to not appre-
ciate the importance of achieving and maintaining good 
dental health through self-performed daily oral hygiene 
and regular dental check-ups. This was a common theme 
reported by participants in relation to patients’ outlook 
on oral health issues as a whole and not just related to 
the specific preventative strategies for BRONJ. This was 
identified as a barrier in the management of this patient 
population and a focus for patient education.
‘I would say that their oral hygiene was not particularly 
great. I think it's probably just not wanting to go to 
the dentist and fear of the dentist.’ (P9)
Patients often tend to forget the initial advice given to 
them and reminders or continuous advices are necessary 
to enhance patient education. Teamwork highlights the 
importance of specific counselling and reinforces the 
advice that is given to patients.
‘If a new drug is initiated, that is the time to reinforce 
what the patients been told about the drug and you 
know to give them the message. I think the more 
reinforcement and the more information the better.’ 
(GP2)
Wider context
Both GPs and pharmacists identified that there is reluc-
tance among certain patients to seek dental advice. A 
number of reasons were proposed for this, including the 
cost of dental treatment, a general lack of oral health 
awareness and patients with dental phobias.
‘The processes of how you get people to take their 
dental health seriously are very difficult. The ones 
that pay for dentistry are likely to be the ones with 
good teeth, the others who get free treatment just 
don’t access it.’ (GP3)
Access to dentists was also felt to be an issue that both 
pharmacists and GPs had encountered, specifically the 
availability of dental services for patients and referral 
pathways between professions.
‘Some people don’t even have an NHS dentist. I am 
aware of where I work, there was a dentist upstairs, 
but it wasn’t an NHS dentist. I think when you want to 
refer someone to another service you know it is going 
to be a little bit more problematic than just making 
an appointment with a GP for example.’ (P2)
Participants all described a heavy workload and that in 
the small amount of time that they had with each patient, 
they would have to prioritise the information they gave 
to patients.
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‘In that 2 min that you have got to hand something 
out to somebody, you concentrate on the important 
things, such as how to take it, to get their concordance 
and compliance.’ (P2)
A lack of communication between both GPs/phar-
macists and dentists was identified as a major barrier. 
The absence of a formal referral process between phar-
macists, GPs and the dental profession was highlighted 
throughout. This was felt to be an issue related to BRONJ 
and represented a wider problem in the management 
of oral health in primary care. In order to successfully 
manage the risk of BRONJ, it was clear from interviewees 
that communication between professionals is key.
‘I think maybe there needs to be a little bit more 
communication involved with pharmacists. The 
triangle, pharmacist, dentist and prescriber.’ (P2)
‘Some sort of shared record keeping where you could 
enter into the system. You have done a review and 
these side effect were discussed with the patient, that 
would be brilliant. That would make it part of that 
clinical record, I'd know about it, the patient would 
know about it. I think that would work very well.’ 
(GP7)
One of the key areas identified by all pharmacists 
and some of the GPs was the benefit of Medication Use 
Reviews (MURs) and the New Medicine Service (NMS) in 
community pharmacies. The MUR and NMS services are 
both advanced service within the National Health Service 
(NHS) Community Pharmacy Contractual Framework 
in England. An MUR is a structured, adherence-centred 
review of patients prescribed multiple medicines and 
the NMS service provides support for patients with long-
term conditions that have been newly prescribed a medi-
cine.19 20
These services provide pharmacies with both the time 
and structure to provide more detailed advice to patients 
on medications. Bisphosphonates are not currently spec-
ified in either service. Although it was felt that many 
drugs should be included, all participants identified that 
bisphosphonates should be included in these services due 
to their specific administration instructions and potential 
for side effects.
‘I think during an MUR you certainly have more time 
to focus on the individual drugs and then it kind of 
triggers in your brain the more important things that 
you should be speaking to them about.’ (P2)
Professional
GPs acknowledged their role as the prescriber and the 
need to counsel patients on the side effects of their medi-
cation. Both prescribers and pharmacists were in agree-
ment that pharmacists are the experts on medications 
and they have a role to play in counselling patients on 
safe and effective use of medicines.
‘I think counselling about medication is far better 
done by the pharmacists. I think the other reason is 
perhaps, when a patient sees a doctor they expect to 
be able to discuss all aspects of their lives and their 
care. When they see the pharmacist, they know they 
are seeing the pharmacist about their medication. I 
think it is much easier for the pharmacist to keep the 
patient focused on the drugs and the patient to stay 
focused on the drugs.’ (GP1)
Although pharmacists acknowledged their role in coun-
selling patients on medications, a number of them felt that 
if a patient needs to be dentally fit before commencing 
bisphosphonate therapy, then it would be the respon-
sibility of the GP to arrange this. Although in many 
cases GPs would be responsible for initially prescribing 
bisphosphonates and their continued prescribing, it was 
commented that bisphosphonates can, at times, be initi-
ated in secondary care. This was certainly the case for 
intravenous bisphosphonates with all GPs and pharma-
cists reporting little or no experience with prescribing or 
dispensing these products. As intravenous bisphospho-
nates are usually prescribed in secondary care, it was felt 
by some of the participants that this was a potential risk, 
as they can be missed on medication lists.
‘Making sure that the dental check has been done and 
that they’re healthy should actually be done before 
you prescribe medication, because if you prescribe a 
medicine without knowing that, then technically how 
do you know that it’s going to be safe for the patient 
to take. I think my role as a pharmacist is certainly to 
promote that it’s been done, and if it hasn’t to take 
further steps with the patient.’ (P7)
A number of participants also described limited educa-
tion or training in relation to oral and dental health.
‘We have no training in dental care. You know to 
brush your teeth and that’s what you say to people. 
I think, I don’t know, maybe we should have some 
more training.’ (GP5)
‘No not really, a little bit maybe in lectures at univer-
sity but not with dentists, we have worked quite closely 
with the doctors but not with dentists.’ (P1)
DIscussIOn
summary of main indings
It is apparent that both sets of participants (GPs and phar-
macists) had limited knowledge of BRONJ, in particular 
in relation to its prevalence and the morbidity associated 
with the condition. As BRONJ is relatively uncommon, 
the majority of participants also lacked first-hand experi-
ence of managing affected patients.
Due to the complexity of this patient group and 
bisphosphonates as a therapeutic class, interviewees 
assigned priorities in relation to clinical management and 
in patient education. Consultations would usually focus 
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on the specific administration requirements and more 
common GI-related adverse effects as opposed to the risk 
of developing BRONJ and the need for good oral and 
dental health.
Awareness of the issue was thought to be a key barrier 
to implementing preventative strategies in this patient 
group; however, wider issues in relation to the attitudes 
of patients towards oral health, a reluctance to attend the 
dentist and difficulties in accessing dental services were 
thought to be potential barriers for patients. The lack of 
communication between the professions was also cited as 
a key issue that needs to be addressed for the successful 
implementation of any future collaborative preventative 
strategies in this patient group, with the MUR and NMS 
pharmacy services identified as a potential facilitator.
Pharmacists and GPs reported good working relation-
ships but interprofessional educational opportunities with 
dental colleagues appear to have been limited in scope 
or non-existent, and were cited as a potential enabler for 
improving multidisciplinary working.
comparison with existing literature
Knowledge on the oral risks associated with bisphospho-
nate therapy has been reported to be limited.15 All partic-
ipants interviewed in this research reported being aware 
of the risk, although this was introduced before the inter-
views in the participant information leaflet.
Many of the participants would not routinely mention 
the risk of osteonecrosis of the jaw when prescribing 
bisphosphonates or when counselling patients about the 
medication. This is consistent with a small quantitative 
study that identified only 17% of patients prescribed oral 
bisphosphonates were aware of the risk of BRONJ, with 
the majority of these patients acquiring this knowledge 
from patient information leaflets and not from their GP.21
All participants reported reluctance among patients to 
attend dental appointments, with a significant proportion 
of their patients being either not registered with a dentist 
or not regular attendees. This is consistent with NHS 
dental statistics, which state that only 52% of the adult 
population has seen an NHS dentist within the previous 
24 months.22
A number of clinical guidelines and patient safety 
alerts recommend that patients should be counselled on 
the risk of BRONJ and advised to seek a dental check-up 
prior to initiating bisphosphonate therapy.5 8 Our data 
suggest that this does not appear to routinely happen. 
A recent study in Japan reported that 62% (n=629) of 
physicians did not request oral healthcare by a dentist 
before commencing bisphosphonate therapy and 72% of 
participants reported no cooperation between physicians 
and dentists. They concluded that a strategy for sharing 
information among physicians, dentists and patients is 
required to reduce the incidence of osteonecrosis of the 
jaw associated with osteoporosis treatment.23 The popula-
tion studied were all members of the Japan Osteoporosis 
Society; the nature of this sample and therefore interest 
in osteoporosis management of the participants could 
potentially explain the higher rates of dental referrals 
than reported in other studies.
The MUR and NMS were identified as potential facil-
itators in the prevention of BRONJ. Bisphosphonates 
are not directly specified in either of these services at 
present, although participants were in agreement that it 
would be beneficial for them to be included. The litera-
ture to support both services is mixed; a detailed review 
by the University of Nottingham found that the imple-
mentation of the NMS was constrained by the quality of 
the pharmacist’s relationship with GPs. They found that 
poor communication between the professions and a lack 
of awareness or understanding by GPs about the service 
resulted in a lack of referrals; this is consistent with state-
ments from some of the GPs in this study. Pharmacists 
also suggested that GPs were not interested in the NMS as 
it potentially encroached on professional boundaries and 
duplicated work undertaken by the GP.24 In comparison, 
the GPs in this study, despite having limited knowledge 
of the service, were all supportive of its role and the rein-
forcement of important counselling points was thought 
to be a key responsibility of the pharmacist.
Pharmacists are subject to organisational pressures to 
meet targets around the MUR service which has been 
reported to result in their offering the service to patients 
who meet the minimum inclusion criteria and avoiding 
offering the service to more complex patients due to time 
pressures.25 This potentially impacts the patient group 
under study as a clear theme that emerged from the data 
was the complexity and polypharmacy issues of patients 
taking bisphosphonates.
An ethnographic study utilising observations and 
patient interviews in two English community pharma-
cies found that patients generally were positive about the 
MUR, and patients tended to view the pharmacist as an 
expert on medicines. However, some participants felt wary 
of the pharmacist’s involvement, considering that the 
pharmacists were deliberately or intentionally bypassing 
the GP. This study also found that there was little evidence 
to suggest that the professions were collaborating to iden-
tify patients who could benefit from the service.25
limitations
The study was based around the a priori issue of limited 
knowledge among GPs and pharmacists in the prevention 
of BRONJ; the concept of BRONJ was introduced during 
the patient information leaflet, therefore exposing partic-
ipants to the concept before the interview.
Participants were all located in the North East of 
England and Cumbria; this therefore may impact on the 
transferability of findings to other geographical locations 
or healthcare settings. For example, a variation in the 
access to dental services in a particular location may influ-
ence the practice of participants and patients.
Future work and implications for clinical practice
This study has highlighted a number of areas for 
future study. However, missing from this study and the 
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wider literature is the dental profession’s insight into 
the interprofessional prevention of BRONJ. A recent 
publication in British Dental Journal highlighted the 
opportunities for interprofessional working between 
pharmacists and dentists; with a particular focus on 
chronic diseases, it was suggested that dental and phar-
macy teams should take action to improve communi-
cation and devise schemes for collaborative working.26 
Published clinical guidelines recommend that patients 
should be referred for dental assessment and treat-
ment prior to initiation on bisphosphonate therapy, 
but it is apparent this is not happening. The impact 
of this on dentists and their perspective on how the 
professions can collaborate to improve patient care 
would be important to consider before implementing 
any preventative strategies.
Raising awareness of the rare side effects of medi-
cines is an important consideration when prescribing; 
explicitly pointing out rare side effects may create 
adherence problems and result in non-compliance 
with a potentially beneficial medicine which needs 
to be balanced against fully informing patients about 
the associated risks. Further research with patients to 
explore this issue would help guide practitioners and 
would be applicable to many other rare conditions 
and medicines.
The patient remains the central focus of the healthcare 
team, and therefore engaging patients in the manage-
ment of their health is essential when introducing preven-
tion strategies for BRONJ. Attitudes of patients towards 
the roles of the various team members and their priorities 
or expectations when being prescribed a new medicine 
will guide the development of such services.
cOnclusIOn
Both GPs and pharmacists demonstrated relatively 
limited knowledge in relation to BRONJ and the 
preventative strategies recommended in the litera-
ture. Patients prescribed bisphosphonates often have 
complex medical histories, requiring practitioners to 
assign priorities in their management and, as such, 
the measures required to prevent the development of 
BRONJ can be overlooked.
Prescribing rates of bisphosphonates are increasing, 
with an ageing population and increasing emphasis on 
treating and preventing conditions such as osteoporosis. 
Therefore, the incidence of BRONJ is likely to increase; 
this may continue to be the case unless changes are made 
to current practice. Preventive measures should be imple-
mented and further research performed to assess the 
effectiveness of such interventions.
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